Education
About Us
Working with TipRanks
Follow Us
Molecular Partners (MOLN)
NASDAQ:MOLN
MOLN Stock Chart & Stats
$4.21
-$0.03(-0.55%)
At close: 4:00 PM EST
$4.21
-$0.03(-0.55%)
Day’s Range― - ―
52-Week Range$3.36 - $5.91
Previous CloseN/A
Volume8.30K
Average Volume (3M)2.31K
Market Cap
$168.11M
Enterprise Value$29.49M
Total Cash (Recent Filing)$104.52M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Mar 12, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding40,374,640
10 Day Avg. Volume2,377
30 Day Avg. Volume2,311
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.04
Price to Sales (P/S)29.53
P/FCF Ratio-2.45
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.73
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$10.00Price Target Upside137.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 1/2a data for MP0533 showed objective clinical responses including multiple complete remissions among treated patients, supporting the asset's potential clinical value.
Imaging And BiodistributionMP0712 imaging and dosimetry updates indicate tumor-selective uptake with reduced liver accumulation and a modest serum half-life extension, features that could enable higher tumor radiation delivery with fewer off-target effects.
Supply Chain And PartnershipsThe Orano Med partnership secures access to lead production capacity and shares capital and operating costs, reducing supply and manufacturing risk for planned radiopharmaceutical programs.
Bears Say
Immunogenicity RiskAnti-drug antibodies coincided with reduced MP0533 exposure and loss of T‑cell activation in a substantial portion of patients, which may undermine clinical durability and response rates.
Premedication Strategy RiskObinutuzumab pretreatment produced only limited benefit in enhancing responses, signaling challenges for premedication approaches intended to improve MP0533 efficacy.
Target Expression RiskVery low cell-surface density of DLL3 raises concern about target availability across tumors, potentially complicating patient selection and the broad applicability of DLL3-directed therapies.
Molecular Partners News
MOLN FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.36 and its highest was $5.91 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is $168.11M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Mar 12, 2026 which is in 55 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Aug 25, 2025. The company reported -$0.686 earnings per share for the quarter, missing the consensus estimate of -$0.474 by -$0.212.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate is -0.39.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,374,640 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.686 in its last earnings report, missing expectations of -$0.474. Following the earnings report the stock price went down -7.82%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MOLN Stock 12 Month Forecast
Average Price Target
$10.00
▲(137.53% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
8.86% Other Institutional Investors
91.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---